Close rivalries among US NSCLC medical affairs teams. Will your team come out on top?
In the US, nearly all of the NSCLC medical affairs teams we surveyed are running neck and neck with at least one rival. The 100 medical oncologists we polled say that each of those teams needs improvement in at least one specific area, but are those targeted improvements enough to put your team ahead of the competition?
Discover all the ways you can improve your medical affairs services in Medical Affairs Reputations: NSCLC (US). Comparing 13 major NSCLC treatments from ARIAD Pharmaceuticals, Roche, Eli Lilly, Boehringer Ingelheim, AstraZeneca, Merck & Co., Pfizer and Novartis this report reveals:
- How medical oncologists rate your team overall, and on 12 key medical affairs services.
- Which medical affairs services are most important.
- How, and how often medical oncologists want to meet with your team.
- What you can do to improve your medical affairs services.
Interested in the EU market? Click here to see the EU Edition.
- All to play for at the top, limited options at the bottom. Only 3 points separate the top 2 leading brands in terms of overall quality of interactions, whereas brands at the bottom could struggle to make up ground.
- Information is the #1 priority. The most important medical affairs services all relate to providing information that doctors can use to make better treatment decisions.
- Huge variations in activity. In the past six months, only 2 of the 13 teams interacted with more than 70% of doctors surveyed, and the least active teams saw no more than 44% of them.
- Doctors want to see teams in-person and not too often. The report reveals how, and how frequently your team should engage.
- Digital interaction still some way off becoming the norm. For the most part, doctors want personal interactions, not emails or phone calls.
- Alunbrig (brigatinib; ARIAD Pharmaceuticals)
- Avastin (bevacizumab; Roche)
- Alecensa (alectinib; Roche)
- Cyramza (ramucirumab; Eli Lilly)
- Gilotrif (afatinib; Boehringer Ingelheim)
- Iressa (gefitinib; AstraZeneca)
- Keytruda (pembrolizumab; Merck & Co.)
- Opdivo (nivolumab; Bristol-Myers Squibb)
- Tagrisso (osimertinib; AstraZeneca)
- Tarceva (erlotinib; Roche)
- Tecentriq (atezolizumab; Roche)
- Xalkori (crizotinib; Pfizer/Merck Group)
- Zykadia (ceritinib; Novartis)
Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of 13 medical affairs teams—answering important questions like:
What do physicians need?
- How, and how often are they using your medical affairs team?
- What services do they consider most important?
- How often should you contact them? What channels are best?
- How memorable are your team’s interactions with doctors?
- How do doctors rank your team for performance and satisfaction in 12 key areas?
- How does your team compare to the competition—in each area, and overall?
- Are you delivering the services that are most important to doctors?
- Where do you need to improve?
- How can your team enhance its services?
We surveyed 100 US medical oncologists, chosen from the largest community of validated physicians in the world.
- Have been practicing for between 3 and 35 years
- See at least 5 patients with NSCLC ina typical month
- Devote at least 50% of their time to direct patient care
- Have interacted with at least one listed product’s medical affairs team in the past 6 months.
2. Current Status of Interactions with Different Medical Affairs Teams
2.1 Interactions in the past 6 months with Medical Affairs teams for each product
2.2 Current frequency of interactions with medical affair teams for each product
3. Competitive Evaluation of Medical Affairs Teams Performance on Various Attributes
1. Evaluation of overall quality of interactions with Medical Affairs teams for each product
2. Attribute importance of Medical Affairs teams roles to physicians’ practice
3. EdgeMap analysis – Competitive evaluation on Medical Affairs teams performance on attributes
4. Competitive evaluation of physicians satisfaction of interaction with Medical Affairs teams
5. Need-Gap analysis by product
4. Preferred Interaction Media, Frequency, and Suggestions for Improvement
1. Preferred interaction media and frequency, and suggestions for improvement